🧬 GLP-1 Series: Lilly’s TRANSCEND-T2D-2 topline results

I’ve previously described Eli Lilly as the NVIDIA of healthcare.

Its momentum in China’s GLP-1 market is worth watching. In Q2 2026, Lilly led weekly GLP-1 weight-loss drug sales on major Chinese e-commerce platforms.

Today, Lilly announced the topline results from TRANSCEND-T2D-2.

Now, let’s talk about retatrutide.

At 80 weeks, retatrutide delivered more than double the weight loss of Ozempic 2 mg:

• Weight loss: 20.9% vs 9.4%

• A1c reduction: 2.2 vs 1.8 percentage points

Why is retatrutide different?

It’s a triple-hormone receptor agonist targeting:

• GLP-1: appetite regulation and glucose control

• GIP: glucose-dependent insulin secretion and metabolic regulation

• Glucagon: may increase energy expenditure

Unlike semaglutide (GLP-1) or tirzepatide (GLP-1 + GIP), retatrutide activates all three pathways.

The trade-off? Gastrointestinal side effects and treatment discontinuations were more frequent at the higher dose.

Why does this matter? Obesity is linked to multiple cardiometabolic conditions, including type 2 diabetes, hypertension, dyslipidemia, heart attack, OSA, PAD, MASLD and HFpEF.

The big question: Will greater weight loss translate into fewer heart attacks, strokes, and cardiovascular deaths?

Retatrutide remains investigational and is not FDA-approved.

Educational purposes only. Not medical or financial advice.

Source: Lilly’s TRANSCEND-T2D-2 topline results, October 28, 2026.